Research programme: incrementally modified drugs - Hyundai Pharmaceuticals

Drug Profile

Research programme: incrementally modified drugs - Hyundai Pharmaceuticals

Alternative Names: HOB 060; HOB 071; HOB 075; HTB 005; HTB 006; HTB 060

Latest Information Update: 20 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hyundai Pharmaceutical
  • Class
  • Mechanism of Action Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alopecia; Depressive disorders; Obesity
  • Research Hyperlipidaemia

Most Recent Events

  • 07 Dec 2015 Early research in Hyperlipidaemia in South Korea (unspecified route) prior to December 2015
  • 07 Dec 2015 Preclinical trials in Alopecia in South Korea (unspecified route) prior to December 2015
  • 07 Dec 2015 Preclinical trials in Depressive disorders in South Korea (unspecified route) prior to December 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top